Systematic review with meta-analysis: Non-alcoholic steatohepatitis-a case for personalised treatment based on pathogenic targets

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 1, 2014, Pages 3-14

  Younossi, Z M ^a,b   Reyes, M J ^a,b   Mishra, A ^a,b   Mehta, R ^a,b   Henry, L ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CHINESE DRUG; FRUCTOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; CALORIC RESTRICTION; CARBOHYDRATE INTAKE; CLINICAL TRIAL (TOPIC); COFFEE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERANCE; EXERCISE; FAT INTAKE; FATIGUE; FUNCTIONAL STATUS; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION;

BARIATRIC SURGERY; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; LACTONES; METABOLIC SYNDROME X; METFORMIN; THIAZOLIDINEDIONES; URSODEOXYCHOLIC ACID; VITAMIN E; WEIGHT LOSS;

EID: 84889634755     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12543     Document Type: Article

References (91)

1. Paredes AH, Torres DM, Harrison SA,. Nonalcoholic fatty liver disease. Clin Liver Dis 2012; 16: 397-419.
2. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and managements of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
3. Karlas T, Wiegand J, Berg T,. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013; 27: 195-208.
4. Yilmaz Y,. Review Article: non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Ailment Pharmacol Ther 2012; 36: 345-52.
5. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE,. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 13-24.
6. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA,; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-20.
7. Moore JB,. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211-20.
8. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS,. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96.
9. Marra F, Lotersztajn S,. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013; 19: 5250-69.
10. Schuppan D, Schattenberg JM,. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28 (Suppl. 1): 68-76.
11. Attar B, Van Thiel DH,. Current concepts and management approaches in non alcoholic fatty liver disease. Sci World J 2013; 2013: 1-10.
12. Ibrahim MA, Kelleni M, Geddawy A,. Non alcoholic fatty liver disease: current and potential therapies. Life Sci 2013; 92: 114-8.
13. Baranova A, Lal P, Birerdinc A, Younossi ZM,. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 17: 91.
14. Bonnet F, Ducluzeau PH, Gastaldelli A, et al,.; RISC Study Group. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 2011; 60: 1660-7.
15. Hirata T, Tomita K, Kawai T, et al,. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol 2013; 2013: 587140.
16. Kondo K, Ishigaki Y, Gao J, et al,. Bach1 deficiency protects pancreatic β-cells from oxidative stress injury. Am J Physiol Endocrinol Metab 2013; 305: E641-8.
17. Baršic̈ N, Lerotic̈ I, Smirčic̈-Duvnjak L, Tomašic̈ V, Duvnjak M,. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 3945-54.
18. Weijers G, Starke A, Thijssen JM, et al,. Transcutaneous vs. intraoperative quantitative ultrasound for staging bovine hepatic steatosis. Ultrasound Med Biol 2012; 38: 1404-13.
19. Zelber-Sagi S, Kessler A, Brazowsky E, et al,. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
20. Harrison SA, Brunt EM, Fecht WJ, et al,. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology 2009; 49: 80-6.
21. Haukeland JW, Konopski Z, Eggesbo HB, et al,. Metformin in patients with non-alcoholic fatty liver disease; a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
22. Loomba R, Lutchman G, Kleiner DE, et al,. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 29: 172-82.
23. Nair S, Diehl AM, Wiseman M, et al,. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
24. Shields WW, Thompson KE, Grice SA, et al,. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009; 2: 157-63.
25. Lavine JE, Schwimmer JB, Van Natta ML, et al,. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 2011; 305: 1659-68.
26. Neuschwander-Tetri BA, Brunt EM, Weheier KR, Oliver D, Baon BR,. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
27. Ratziu V, Giral P, Jacqueminet S, Charlotte F, et al,. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
28. Ratziu V, Charlotte F, Bernhardt C, Giral P, et al,. Long-term efficacy of Rosiglitazone for nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-53.
29. Belfort R, Harrison SA, Brown K, et al,. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
30. Aithal GP, Thomas JA, Kaye VP,. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
31. Chalasani NP, Sanyal AJ, Kowdley KV, et al,.; NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88-96.
32. Sanyal AJ, Chalasani N, Kowdley KV, et al,. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
33. Lindor KD, Kowdley KV, Heathcote EJ, et al,. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
34. Schauer PR, Kashyap SR, Wolski K, et al,. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-76.
35. Dufour JF, Oneta CM, Gonvers JJ, et al,.; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006 Dec; 4: 1537-43.
36. Leuschner UF, Lindenthal B, Herrmann G, et al,.; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-9.
37. Ratziu V, de Ledinghen V, Oberti F, et al,.; FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-9.
38. Eckard C, Cole R, Lockwood J, et al,. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013; 6: 249-59.
39. Peng L, Wang J, Li F,. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011; 6: CD003619.
40. Thoma C, Day CP, Trenell MI,. Lifestyle interventions for the treatment of non-41 Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360: 859-73.
41. Franz MJ, VanWormer JJ, Crain AL, et al,. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 1755-67.
42. Hayward CS, Lockwood J, Williams CD, Cole RE, Torres DM, Harrison SA,. Lifestyle modification and NAFLD: a prospective randomized trial. Hepatology 2010; 52 (S4): 622A.
43. Bonekamp S, Barone BB, Clark J, Stewart KJ,. The effects of an exercise training intervention on hepatic steatosis. Hepatology 2008; 48 (Suppl. 1): 806A.
44. Johnson NA, Sachinwalla T, Walton DW, et al,. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-12.
45. St. George A, Bauman A, Johnston A, et al,. Independent effects of physical activity in patients with non-alcoholic fatty liver. Hepatology 2009; 50: 68-76.
46. Hallsworth K, Fattakhowa G, Hollingsworth K, et al,. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-83.
47. Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL,. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010; 52: 112-6.
48. Newton JL,. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 214-9.
49. Price JK, Srivastava R, Bai C, Diao G, Gerber LH, Younossi ZM,. Comparison of activity level among patients with chronic liver disease. Disabil Rehabil 2013; 35: 907-12.
50. Gerber CE, Blissmer B, Deschenes MR, et al,. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43: 1334-59.
51. Musso G, Bo S, Cassader M, De Michieli F, Gambino R,. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr 2013; 28: 895-906.
52. Petta S, Marchesini G, Caracausi L, et al,. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol 2013; 58: S199.
53. Simopoulos AP,. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients 2013; 5: 2901-23.
54. Capanni M, Calella F, Biagini MR, et al,. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-51.
55. Klatsky AL, Morton C, Udaltsova N, Friedman GD,. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166: 1190-5.
56. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM,. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 76-82.
57. Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP,. Coffee induces expression of glucuronosyl-transferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139: 1699-710.
58. Gressner OA,. Less Smad2 is good for you! A scientific update on coffee's liver benefits. Hepatology 2009; 50: 970-8.
59. Crozier TW, Stalmach A, Lean ME, Crozier A,. Espresso coffees, caffeine and chlorogenic acid intake: potential health implications. Food Funct 2012; 3: 30-3.
60. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA,. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55: 429-36.
61. Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S,. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-6.
62. Saab S, Mallam D, Cox GA, Tong MJ,. Impact of coffee on liver diseases; a systematic review. Liver Int 2013; doi: 10.1111/liv.12304 [Epub ahead of print].
63. Modi AA, Feld JJ, Park Y, et al,. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51: 201-9.
64. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al,. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011; 54: 1123-9.
65. Yki-Jarvinen H,. Thiazolidinediones. New Engl J Med 2004; 351: 1106-18.
66. Lutchman G, Modi A, Kleiner DE, et al,. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatol Baltim Md 2007; 46: 424-9.
67. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al,. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
68. Lazaridis KN, Gores GJ, Lindor KD,. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35: 134-46.
69. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
70. Pathil A, Mueller J, Warth A, et al,. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012; 55: 1369-77.
71. Musso G, Anty R, Petta S,. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Curr Pharm Des 2013; 19: 5297-313.
72. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
73. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-26.
74. Shi KQ, Fan YC, Liu WY, et al,. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systemic review and meta-analysis. Mol Biol Rep 2012; 39: 9715-22.
75. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J,. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-51.
76. Zein CO, Lopez R, Fu X, et al,. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012 Oct; 56: 1291-9.
77. Iacono A, Raso GM, Canani RB, et al,. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011; 22: 699-711.
78. Stephen S, Baranova A, Younossi ZM,. Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol 2012; 6: 163-71.
79. Tai CM, Huang CK, Hwang JC,. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012; 22: 1016-21.
80. Mummadi RR, Kasturi KS, Chanarreddygari S, Sood CK,. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-402.
81. Mathurin P, Hollebecque A, Arnalsteen L, et al,. Prospective study of the long term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-40.
82. Ikramuddin S, Korner J, Lee WJ, et al,. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013; 309: 2240-9.
83. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M,. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; 1: CD007340.
84. Burza MA, Romeo S, Kotronen A, et al,. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) Study. PLoS ONE 2013; 8: e60495.
85. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA,. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007; 17: 486-92.
86. Vargas V, Allende H, Lecube A, et al,. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol 2012; 4: 382-8.
87. Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC,. Effect of bariatric surgery on liver fibrosis. Obes Surg 2012; 22: 1044-9.
88. Klein S, Mittendorfer B, Eagon JC, et al,. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 1564-72.
89. Furuya CK Jr, de Oliveira CP, de Mello ES, et al,. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007; 22: 510-4.
90. Scribner KB, Pawlak DB, Ludwig DS,. Hepatic steatosis and increased adiposity in mice consuming rapidly vs. slowly absorbed carbohydrate. Obesity (Silver Spring) 2007; 15: 2190-9.
91. Skoien R, Richardson MM, Jonsson JR, et al,. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013; 33: 624-32.